Mark Fenton

7.7k total citations · 1 hit paper
69 papers, 4.2k citations indexed

About

Mark Fenton is a scholar working on Psychiatry and Mental health, General Health Professions and Pharmacology. According to data from OpenAlex, Mark Fenton has authored 69 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Psychiatry and Mental health, 12 papers in General Health Professions and 10 papers in Pharmacology. Recurrent topics in Mark Fenton's work include Schizophrenia research and treatment (25 papers), Urban Transport and Accessibility (10 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Mark Fenton is often cited by papers focused on Schizophrenia research and treatment (25 papers), Urban Transport and Accessibility (10 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Mark Fenton collaborates with scholars based in United Kingdom, United States and Canada. Mark Fenton's co-authors include Clive E Adams, Lester Firkins, Austin Lockwood, Caroline Bradley, Max Marshall, Aidan Coffey, Olivia McAuliffe, Katherine Cowan, Iain Chalmers and Sally Crowe and has published in prestigious journals such as Circulation, Cochrane Database of Systematic Reviews and The British Journal of Psychiatry.

In The Last Decade

Mark Fenton

69 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Unpublished rating scales: A major source of bias in randomised controlled trials of treatments for schizophrenia

2000 617 citations Max Marshall, Austin Lockwood et al. The British Journal of Psychiatry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Fenton United Kingdom	33	1.4k	1.0k	591	471	427	69	4.2k
Tommi Härkänen Finland	39	1.2k 0.8×	1.2k 1.2×	889 1.5×	753 1.6×	239 0.6×	177	6.0k
Machteld Huber Netherlands	21	371 0.3×	261 0.3×	900 1.5×	485 1.0×	348 0.8×	57	3.3k
Karen J. Coleman United States	51	778 0.6×	1.4k 1.4×	1.5k 2.6×	2.1k 4.4×	53 0.1×	217	7.9k
David Wilson Australia	40	404 0.3×	1.3k 1.3×	1.3k 2.1×	929 2.0×	53 0.1×	137	7.4k
Ville Lehtinen Finland	43	2.0k 1.4×	2.3k 2.2×	1.3k 2.2×	520 1.1×	446 1.0×	129	5.7k
Julie Morris United Kingdom	40	714 0.5×	301 0.3×	574 1.0×	462 1.0×	90 0.2×	118	4.8k
Michelle M. Haby Australia	36	456 0.3×	624 0.6×	807 1.4×	1.1k 2.3×	25 0.1×	87	4.5k
C. Laird Birmingham Canada	29	612 0.4×	1.6k 1.6×	452 0.8×	2.0k 4.2×	23 0.1×	122	6.5k
J. M. Kinney United States	44	888 0.6×	552 0.5×	1.1k 1.9×	356 0.8×	56 0.1×	140	6.8k
Phillip J. Brantley United States	41	459 0.3×	1.4k 1.4×	1.3k 2.1×	1.6k 3.4×	43 0.1×	149	5.7k

Countries citing papers authored by Mark Fenton

Since Specialization

Citations

This map shows the geographic impact of Mark Fenton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Fenton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Fenton more than expected).

Fields of papers citing papers by Mark Fenton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Fenton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Fenton. The network helps show where Mark Fenton may publish in the future.

Co-authorship network of co-authors of Mark Fenton

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Fenton. A scholar is included among the top collaborators of Mark Fenton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Fenton. Mark Fenton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Young, Deborah Rohm, Angie L. Cradock, Amy A. Eyler, et al.. (2020). Creating Built Environments That Expand Active Transportation and Active Living Across the United States: A Policy Statement From the American Heart Association. Circulation. 142(11). e167–e183. 49 indexed citations

Layton, Alison, N. J. Levell, Matthew J Ridd, et al.. (2015). Identifying acne treatment uncertainties \nvia a James Lind Alliance Priority \nSetting Partnership. University of Huddersfield Repository (University of Huddersfield). 40 indexed citations

Layton, Alison, N. J. Levell, Matthew J Ridd, et al.. (2015). Identifying acne treatment uncertainties via a James Lind Alliance Priority Setting Partnership. BMJ Open. 5(7). e008085–e008085. 9 indexed citations

Crowe, Sally, Mark Fenton, Matthew Hall, Katherine Cowan, & Iain Chalmers. (2015). Patients’, clinicians’ and the research communities’ priorities for treatment research: there is an important mismatch. Research Involvement and Engagement. 1(1). 14–14. 224 indexed citations

Corcoran, Michael P., et al.. (2014). The Built Environment, Physical Activity, and Aging in the United States: A State of the Science Review. Journal of Aging and Physical Activity. 23(2). 323–329. 90 indexed citations

Fenton, Mark. (2012). Community Design and Policies for Free-Range Children: Creating Environments That Support Routine Physical Activity. Childhood Obesity. 8(1). 44–51. 16 indexed citations

Fenton, Mark, R. Paul Ross, Olivia McAuliffe, Jim O’Mahony, & Aidan Coffey. (2011). Characterization of the staphylococcal bacteriophage lysin CHAPK. Journal of Applied Microbiology. 111(4). 1025–1035. 56 indexed citations

Wang, Jijun, Ichiro M Omori, Mark Fenton, & Bernardo Soares. (2010). Sulpiride augmentation for schizophrenia. Cochrane Database of Systematic Reviews. 2012(2). CD008125–CD008125. 27 indexed citations

Fenton, Mark, Olivia McAuliffe, Jim O’Mahony, & Aidan Coffey. (2010). Recombinant bacteriophage lysins as antibacterials. PubMed. 1(1). 9–16. 173 indexed citations

10.

Elwyn, Glyn, Sally Crowe, Mark Fenton, et al.. (2010). Identifying and prioritizing uncertainties: patient and clinician engagement in the identification of research questions. Journal of Evaluation in Clinical Practice. 16(3). 627–631. 80 indexed citations

11.

Fenton, Mark, Pat G. Casey, Colin Hill, et al.. (2010). The truncated phage lysin CHAP_keliminatesStaphylococcusaureusin the nares of mice. PubMed. 1(6). 404–407. 73 indexed citations

12.

Fenton, Mark, et al.. (2006). Pharmacological interventions for people with borderline personality disorder. Cochrane Database of Systematic Reviews. CD005653–CD005653. 96 indexed citations

13.

Fenton, Mark. (2005). Battling America's Epidemic of Physical Inactivity: Building More Walkable, Livable Communities. Journal of Nutrition Education and Behavior. 37. S115–S120. 35 indexed citations

14.

El-Sayeh, Hany G, et al.. (2003). Gross Domestic Product (GDP) and productivity of schizophrenia trials: an ecological study. BMC Psychiatry. 3(1). 18–18. 10 indexed citations

15.

Fenton, Stephen J., Elizabeth A. Jackson, & Mark Fenton. (2001). An audit of the ophthalmic division of the accident and emergency department of the Royal Victoria Eye and Ear Hospital, Dublin.. PubMed. 94(9). 265–6. 39 indexed citations

16.

Fenton, Mark, Evandro Silva Freire Coutinho, & Colin Campbell. (2001). Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews. CD000525–CD000525. 25 indexed citations

17.

Duggan, Lorna, et al.. (2000). Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews. CD001359–CD001359. 25 indexed citations

18.

Reilly, J., et al.. (2000). Thioridazine for schizophrenia. Cochrane Database of Systematic Reviews. CD001944–CD001944. 6 indexed citations

19.

Marshall, Max, et al.. (2000). Unpublished rating scales: A major source of bias in randomised controlled trials of treatments for schizophrenia. The British Journal of Psychiatry. 176(3). 249–252. 617 indexed citations breakdown →

20.

Murphy, Bernadette, et al.. (2000). Loxapine for schizophrenia. Cochrane Database of Systematic Reviews. CD001943–CD001943. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact